218 related articles for article (PubMed ID: 9181686)
1. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
3. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs.
Crosasso P; Brusa P; Dosio F; Arpicco S; Pacchioni D; Schuber F; Cattel L
J Pharm Sci; 1997 Jul; 86(7):832-9. PubMed ID: 9232525
[TBL] [Abstract][Full Text] [Related]
5. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
6. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier.
Shih LB; Goldenberg DM; Xuan H; Lu H; Sharkey RM; Hall TC
Cancer Res; 1991 Aug; 51(16):4192-8. PubMed ID: 1868440
[TBL] [Abstract][Full Text] [Related]
8. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
9. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
10. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
11. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
[TBL] [Abstract][Full Text] [Related]
13. Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line.
Tejuca M; Díaz I; Figueredo R; Roque L; Pazos F; Martínez D; Iznaga-Escobar N; Pérez R; Alvarez C; Lanio ME
Int Immunopharmacol; 2004 Jun; 4(6):731-44. PubMed ID: 15135315
[TBL] [Abstract][Full Text] [Related]
14. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
Schrappe M; Bumol TF; Apelgren LD; Briggs SL; Koppel GA; Markowitz DD; Mueller BM; Reisfeld RA
Cancer Res; 1992 Jul; 52(14):3838-44. PubMed ID: 1617657
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs.
Rowland AJ; McKenzie IF; Pietersz GA
J Drug Target; 1994; 2(2):113-21. PubMed ID: 8069589
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
Liu XY; Zhen YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2.
Li S; Zhang XY; Qiao TD; Chen XT; Zhang SY; Chen LJ
Oncol Res; 1992; 4(11-12):447-53. PubMed ID: 1299375
[TBL] [Abstract][Full Text] [Related]
18. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
Patel VF; Hardin JN; Mastro JM; Law KL; Zimmermann JL; Ehlhardt WJ; Woodland JM; Starling JJ
Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
[TBL] [Abstract][Full Text] [Related]
19. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
Dillman RO; Johnson DE; Shawler DL; Koziol JA
Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
